Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus OMNIPEN AMPICILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus OMNIPEN AMPICILLIN.
BACTOCILL vs OMNIPEN (AMPICILLIN)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and peptidoglycan cross-linking.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
Terminal elimination half-life is approximately 1-1.5 hours in adults with normal renal function. In neonates, it may be prolonged to 2-4 hours; in renal impairment, half-life can extend significantly (up to 8-20 hours in severe impairment).
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Renal excretion accounts for approximately 90% of elimination, primarily via tubular secretion and glomerular filtration. Biliary/fecal excretion is minimal, <10%.
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic